Adverse reactions of Mobocertinib/Mobocertinib

Mobocertinib/Mobocertinib(Mobocertinib) is an anti-tumor drug, applicable to patients with epidermal growth factor receptor locally advanced or metastatic non-small cell lung cancer(non-small cell lung cancer) in adults with a pan>(EGFR)exon20insertion mutation and whose disease has progressed during or after platinum-based chemotherapy.

The adverse reactions of moboxetinib are as follows:

QTcProlongation and torsade de pointes:

Life-threateningQTRiskcprolongation, including torsade de pointes. In the pooled safety population, 1.2% of patients had a QTc interval greater than 500ms, 11% of patients had a prolonged QT interval of more than 60 milliseconds from baseline. 1 patient developed 4 grade torsade de pointes. Assess baseline QTc intervals and electrolytes. Correct abnormalities before treatment. MonitorQTc and electrolytes, more frequently in patients with risk factors for QT prolongation. Avoid coadministration with other drugs known to prolong QTcstrong or moderate CYP3A inhibitors. If QTprolongation occurs, temporary interruption of treatment, dose reduction, or permanent discontinuation of c may be necessary.

Interstitial lung disease/Pneumonia:

Among the aggregated security populations,4.3%of patients developed interstitial lung disease(ILD) or pneumonia, resulting in 3 deaths (1.2%). Monitor patients for the development of pulmonary symptoms suggestive of ILD/pneumonia. If ILD/pneumonia is suspected, discontinue treatment immediately. IfILD/pneumonitis is confirmed, permanently discontinuemobosetinib.

Cardiotoxicity:

Mobosetinib has been reported to cause reduced ejection fraction, cardiomyopathy, and congestive heart failure. In the pooled safety population, heart failure occurred in 2.7% of patients, including Grade 3 reactions(1.2%), grade 4 reactions (0.4%), and death (0.4%). Atrial fibrillation, ventricular tachycardia, first-degree atrioventricular block, second-degree atrioventricular block, left bundle branch block, supraventricular premature contractions, and ventricular premature contractions also occurred. Monitor cardiac function, including left ventricular ejection fraction, at baseline and during treatment. If cardiotoxicity occurs, temporary interruption of treatment, dose reduction, or permanent discontinuation of drug therapy may be necessary.

Diarrhea:

Diarrhea is common and may lead to electrolyte imbalance or dehydration with or without renal impairment. In the pooled safety population, diarrhea occurred in 93%of patients. Grade 3 and Grade 4 diarrhea occurred in 20% and 0.4% of patients, respectively. The median time to onset is 5 days, although it can occur within 24 hours of treatment. The average time to resolve an issue is 3 days. Increase fluid and electrolyte intake and initiate antidiarrheal treatment (such as loperamide) at the first onset of diarrheal symptoms. Monitor electrolytes and interrupt medication as needed. Mobosetinibdose adjustment or discontinuation may be necessary.

Fetus/Neonatal morbidity and mortality:

May cause fetal harm; embryonic-fetal toxicity confirmed in animals (i.e., fetal weight loss, embryonic-fetal death)and maternal toxicity (i.e., weight gain and decreased food consumption). Avoid becoming pregnant during treatment. Verify pregnancy status in females of reproductive potential before initiating treatment. Females of reproductive potential should use an effective non-hormonal method of contraception while receiving drug therapy and for 11month after the last dose. Mobosetinibmay interact with hormonal contraceptives, causing them to be ineffective. Male partners of women of reproductive potential should use effective contraception during treatment and for 1 week after the last dose. If used during pregnancy or if the patient or their partner becomes pregnant during treatment, inform of the potential fetal hazard. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.